NEW RESEARCH COLLABORATION AGREEMENT (RCA) BETWEEN THE FDA-CDER(CENTER FOR DRUG EVALUATION AND RESEARCH) AND CHEMOTARGETS
The collaboration aims to enhance CDER’s safety assessments of human pharmaceuticals, supporting theFDA’s mission of protecting public health.
Barcelona, January 15, 2018
Washington D.C., USA: The Food and Drug Administration's Center for Drug Evaluation and Research(FDA/CDER) and Chemotargets will work together under a 5-year Research Collaboration Agreement(RCA).
The primary objective of the research agreement will be to assess the utility and performance of theChemotargets CLARITY® intelligence & discovery platform to predict on-target and off-target activities
using known pharmacology and safety data from experimental studies of small molecular entities.
Evaluating in silico models for broad pharmacological profiling is of interest to CDER to predict potential
adverse events of drugs in development. Additionally, insight into a chemical’s molecular target profile canhelp predict abuse and addiction potential, which may reduce risks associated with exposure to thesesubstances.
The collaboration will involve the use of the Chemotargets CLARITY® platform to evaluate hypotheses on
the toxicological endpoints that are used by CDER to evaluate drug safety. The program identifies theprobable molecular targets and mode of action of small molecules, and their predicted metabolites bysimultaneously and rapidly screening in a single predictive model more than 2,000 mechanisms of action
associated with therapeutic activity and safety liabilities, including hundreds of safety-related mechanisms
annotated with preclinical toxicity and clinical adverse effects. In this respect, Chemotargets CLARITY®
enables predictive compound safety based on careful treatment of FAERS data and the use of somemathematical descriptors to highlight drug safety signals from background noise. CDER will have access toa Chemotargets CLARITY® version based on an expertly-curated training set derived from internal
curation efforts and selected patent data from the GOSTAR database produced by Excelra to ensure acomprehensive coverage of the chemical space. Chemical structure drawing capabilities are available andsupported via the Chemaxon Marvin JS.

About FDA CDER
FDA/CDER performs an essential public health task by making sure that safe and effective drugs areavailable to improve the health of people in the United States. As part of the FDA, CDER regulates overthe-counter and prescription drugs, including biological therapeutics and generic drugs. FDA/CDER's
mission is to protect and promote public health by helping to ensure that human drugs are safe andeffective, meet established quality standards, and are available to patients.

About Chemotargets
Founded on March 2006 as a spin-off company from Dr. Mestres’ Systems Pharmacology lab under theauspices of the IMIM Hospital del Mar Medical Research Institute. Chemotargets offers cutting-edge
validated computational methodologies with top-market predictive performance. The innovation strategy isdriven by access to state-of-the-art research performed at Dr. Mestres Lab @ IMIM, a leading academic
center of excellence based in Barcelona.
Dr. Mestres is the author of more than 150 peer reviewed publications. Chemotargets is currently
recognized as a global leader in the provision of predictive analytics solutions to pharmaceutical andbiotechnology companies and research institutions. Chemotargets' goal is to help the biopharma industry
fast-forward the process of bringing new medicines to market, speeding up drug discovery anddevelopment programs, and making them more cost-efficient.
The recent strategic investment in Chemotargets by the Prous Institute for Biomedical Research will allow
to accelerate product development and acquire new capabilities to support the company’s vision.
For more information: e-mail clarity@chemotargets.com